Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564476 | 0.89 | BACE1 (0.45) | BACE1BACE2CTSDENPEPCASP3 | |
| SCHEMBL31468688 | 0.88 | BACE1 (0.46) | BACE1BACE2CTSDENPEPCASP3 | |
| SCHEMBL29576249 | 0.88 | GNPAT (0.44) | BACE1BACE2ENPEPCASP3CASP8 | |
| SCHEMBL31089740 | 0.88 | ENPEP (0.55) | BACE1BACE2CTSDENPEP | |
| SCHEMBL5194261 | 0.88 | ENPEP (0.55) | BACE1BACE2CTSDENPEP | |
| SCHEMBL19794 | 0.87 | BACE1 (0.52) | BACE1BACE2CTSDENPEP | |
| SCHEMBL4274620 | 0.85 | BACE1 (0.46) | BACE1BACE2CTSDENPEPCASP3 | |
| SCHEMBL31315589 | 0.85 | BACE1 (0.47) | BACE1BACE2CTSDENPEP | |
| SCHEMBL29904046 | 0.85 | BACE1 (0.51) | BACE1BACE2CTSDENPEP | |
| SCHEMBL1674822 | 0.84 | BACE1 (0.47) | BACE1BACE2CTSDENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053744-A1 | NANODELIVERY SYSTEMS FOR EXTENDED RELEASE OF ANTIBODIES | UNIV MARYLAND (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4658299-A1 | SWITCH RECEPTOR FOR USE IN ADOPTIVE CELL THERAPY | Oslo Universitetssykehus HF (NO) | 2025-12-10 | — | — | EP | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-20250011886-A1 | Systems and Methods for Targeting COVID-19 Therapies | AMPEL BIOSOLUTIONS, LLC | 2025-01-09 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| WO-2024160976-A1 | SWITCH RECEPTOR FOR USE IN ADOPTIVE CELL THERAPY | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2024-08-08 | — | — | WO | disclosed |
| US-12023335-B2 | Method for treating pancreatic cancer | PTC THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230018930-A1 | BIOLOGIC PRESERVING COMPOSITION AND METHODS OF USE | AESTHETICS BIOMEDICAL, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230011398-A1 | COMBINATION THERAPY APPROACH TO ELIMINATE HIV INFECTIONS | THE METHODIST HOSPITAL SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220354811-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | INST NAT SANTE RECH MED (FR) | 2022-11-10 | — | — | US | disclosed |
| US-11446330-B2 | Biologic preserving composition and methods of use | AESTHETICS BIOMEDICAL, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220251158-A1 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2022-08-11 | — | — | US | disclosed |
| EP-4037714-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-10 | — | — | EP | disclosed |
| EP-3990002-A1 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | Universitat de Lleida (ES) | 2022-05-04 | — | — | EP | disclosed |
| US-11299526-B2 | p53-BAD fusion proteins | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | BACE1 2824/4885BACE2 1807/4885CTSD 189/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | BACE1 2824/4885BACE2 1807/4885CTSD 189/4885 |
| US-20220354811-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | CASP4, CASP8, CD14 | BACE1 451/4885BACE2 242/4885CTSD 218/4885 |
| US-20260053744-A1 | NANODELIVERY SYSTEMS FOR EXTENDED RELEASE OF ANTIBODIES | NPC1L1, APOL1, ABCB4 | BACE1 128/4885BACE2 170/4885CTSD 1821/4885 |
| US-12023335-B2 | Method for treating pancreatic cancer | TUBB1, TUBB, TUBB3 | BACE1 3617/4885BACE2 2745/4885CTSD 1446/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | BACE1 2824/4885BACE2 1807/4885CTSD 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.